Anodynes HeroPatch demonstrates ability to deliver therapeutic doses of a once-weekly GLP-1 without injections in preclinical trials, pointing to enhanced patient adherence and cost savings BOSTON--(BUSINESS WIRE)--Anodyne Nanotech, a clinical-stage biotech company, today announced promising preclinical results for its proprietary HeroPatch platform, demonstrating the ability to transdermally deliver multi-milligram doses of GLP-1 receptor agonists with greater than 50% bioavailability
A perfect storm for compounders It was Big Pharmas inability to keep up with demand for GLP-1s that initially opened the floodgates to compounded versions in 2022
Each batch is handled according to internal quality standards designed to support consistency, verification, and controlled research workflows
The clinical trials promise life-changing results, and the success stories are everywhere
Our knowledgeable pharmacists can recommend the right antifungal treatments for your needs and help you develop a foot care plan to prevent future infections
But the sheer scale of the obesity crisis means that if (and its a big if) the GLP-1 drugs do have a sustainable impact on weight control, the impact will go way beyond health
